Astra Zeneca Vaccine Protection Reduced After 3 Months

Pharmaceutical

Research has started to show that just three months after being double vaccinated with Oxford-Astra Zeneca, the defense against Covid 19 begins to depreciate. This means that booster vaccines will be necessary for recipients of this vaccine to provide continuous protection against the virus

Researchers have warned that reduction in the inoculation's efficacy is initially seen three months after being double vaccinated. It is at this point that mortality and hospitalisation is 2x more than two weeks post vaccine.

“reduction in the inoculation's efficacy is initially seen three months after being double vaccinated“

The reduction in its defense is predicted to be caused by natural fading of the initial immune cells and antibodies that are prevalent a few days after having a vaccine.

Financial backing for the research was provided by the Medical Research Council, the National Institute for Health Research, the UK Research and Innovation Industrial Strategy Challenge Fund, and Health Data Research UK.

Lead of the study (EAVE II), Professor Aziz Sheikh, said “Vaccines have been a key tool in fighting the pandemic, but waning in their effectiveness has been a concern for a while. By identifying when waning first starts to occur in the Oxford-Astra Zeneca vaccine, it should be possible for governments to design booster programmes that can ensure maximum protection is maintained.

NRS Senior Clinical Research Fellow, Professor Vittal Katikireddi, described how they "studied two million people in Scotland and over 42 million people in Brazil who had received two doses of the Oxford-AstraZeneca vaccine.” In Scotland, the prevalent variant was Delta, whereas in Brazil, it was Gamma. “More than four months after receiving a second dose, the risk of experiencing either a COVID-19 hospitalisation or death was approximately five times greater than the period of maximum vaccine protection after accounting for changes in infection rates and a range of other factors.

Director of Health Data Research UK, Professor Andrew Morris, explained that "By drawing on findings from data sets in two countries with differing dominant COVID-19 variants, the researchers have been able to disentangle vaccine waning from the effects of changes in variants - strengthening the evidence for the ongoing booster programme.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

See all the latest jobs in Pharmaceutical
Return to news